Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Grifols, S.A.

Grifols, S.A. (GRFS) Stock Overview

Explore Grifols, S.A.’s financial performance, market position, analyst ratings, and future outlook.

GRFS●NASDAQ
HealthcareDrug Manufacturers - General
$8.00
$0.010(0.13%)
U.S. Market opens in 63h 30m

Grifols, S.A. (GRFS)

Meyka AI Score

Z

Key Financials

Market Cap6.8B
P/E Ratio10.29
EPS (TTM)$0.87
ROE0.08%
Fundamental Analysis

AI Price Forecasts

1 Month$6.99
3 Months$5.80
1 Year Target$8.92

GRFS Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Grifols, S.A. (NASDAQ: GRFS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Grifols, S.A.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of GRFS on the NASDAQ shows an RSI of 55.13, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $8.92 for the NASDAQ listing.

Key metrics behind Grifols, S.A.'s NASDAQ-traded stock include a P/E ratio of 10.29 and a market capitalization of 6.8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of GRFS on the NASDAQ.

Price Performance (NASDAQ: GRFS)

1-Day Change
0.13%
5-Day Change
1.01%
1-Month Change
3.23%
3-Month Change
-1.36%
6-Month Change
-14.89%
Year-to-Date (YTD) Change
-14.44%
1-Year Change
-20.63%
3-Year Change
-20.24%
5-Year Change
-46.27%
All-Time (Max) Change
20.85%

Contact Information

https://www.grifols.com
34 93 571 02 21
Parque Empresarial Can Sant Joan, Barcelona, CT, 08174

Company Facts

252,580 Employees
IPO DateJun 2, 2011
CountryES
Actively Trading

Frequently Asked Questions